AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
7,263.00
+34.00 (+0.47%)
At close: 4:39PM GMT
Stock chart is not supported by your current browser
Previous close7,229.00
Open7,260.00
Bid7,000.00 x 0
Ask7,640.00 x 0
Day's range7,209.00 - 7,279.00
52-week range109.51 - 8,227.88
Volume1099922
Avg. volume2,194,752
Market cap95B
Beta (3Y monthly)0.20
PE ratio (TTM)45.56
EPS (TTM)159.40
Earnings date14 Feb 2020
Forward dividend & yield2.19 (3.03%)
Ex-dividend date2019-08-08
1y target est78.83
  • Forget a cash ISA! I’d invest in these 3 FTSE 100 shares to double my State Pension
    Fool.co.uk

    Forget a cash ISA! I’d invest in these 3 FTSE 100 shares to double my State Pension

    Why I’d aim to compound my money with these 3 great stocks.

  • Business Wire

    CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia

    AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, a standard chemo-immunotherapy treatment, in patients with previously untreated chronic lymphocytic leukemia (CLL).

  • Does AstraZeneca PLC's (LON:AZN) CEO Salary Reflect Performance?
    Simply Wall St.

    Does AstraZeneca PLC's (LON:AZN) CEO Salary Reflect Performance?

    Pascal Soriot has been the CEO of AstraZeneca PLC (LON:AZN) since 2012. This analysis aims first to contrast CEO...

  • Astrazeneca (LON:AZN): should this FTSE 100 dividend-payer be in your ISA?
    Stockopedia

    Astrazeneca (LON:AZN): should this FTSE 100 dividend-payer be in your ISA?

    When the going gets tough, dividends get cut. Given today's volatile market conditions, mature economic cycle, and historically high dividend yields that are o8230;

  • The biggest deals and attempted deals of the 2010s 
    Yahoo Finance

    The biggest deals and attempted deals of the 2010s 

    As 2019 ends with major deals, Yahoo Finance looks back at the decade on the mergers and acquisitions in Corprorate America.

  • AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
    Reuters

    AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

    The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo. Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

  • Reuters - UK Focus

    REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

    AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer. The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo. Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

  • 3 potentially overvalued FTSE stocks I’d still consider buying on a dip
    Fool.co.uk

    3 potentially overvalued FTSE stocks I’d still consider buying on a dip

    Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

  • Why I’d ditch Bitcoin and invest in these FTSE 100 shares
    Fool.co.uk

    Why I’d ditch Bitcoin and invest in these FTSE 100 shares

    Do these FTSE 100 share prices offer better value to investors than Bitcoin?

  • Why I’d ditch buy-to-let property and buy these 2 FTSE 100 growth shares today
    Fool.co.uk

    Why I’d ditch buy-to-let property and buy these 2 FTSE 100 growth shares today

    I think that these two FTSE 100 (INDEXFTSE:UKX) shares could offer long-term growth potential.

  • Reuters - UK Focus

    China to use drug bulk-buy program to close price gap

    China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement. Many branded versions of drugs are currently more expensive in China than in other major markets. The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China's public hospitals, where most Chinese people buy their drugs.

  • A dirt-cheap FTSE 100 dividend stock I’d buy for my ISA and hold until 2029
    Fool.co.uk

    A dirt-cheap FTSE 100 dividend stock I’d buy for my ISA and hold until 2029

    Attention FTSE 100 investors! This is a dividend stock worth buying now and holding for the next 10 years, says Royston Wild.

  • AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer
    Reuters

    AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer

    The company said the U.S. Food and Drug Administration (FDA) accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer (SCLC). The FDA decision is a boost for the treatment as it competes against similar medicines from rivals Merck and Roche , and follows data in September which showed Imfinzi prolonged survival in SCLC patients when used with chemotherapy.

  • 2020 dividend forecasts: BP, Vodafone and Astrazeneca
    Fool.co.uk

    2020 dividend forecasts: BP, Vodafone and Astrazeneca

    Paul Summers takes a look at what income investors might expect from three FTSE 100 (INDEXFTSE:UKX) favourites next year.

  • Investing £10k in index funds vs FTSE 100 stocks
    Fool.co.uk

    Investing £10k in index funds vs FTSE 100 stocks

    I think diversification is the key to a lower risk financial portfolio.

  • AstraZeneca shares rise on early U.S. approval for leukaemia drug
    Reuters

    AstraZeneca shares rise on early U.S. approval for leukaemia drug

    AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie . AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukaemia in adults. The drug was approved under a new speedy review programme in collaboration with drug watchdogs in Canada and Australia, and was also approved to treat small lymphocytic lymphoma, a similar disease.

  • AstraZeneca shares rise on early U.S. approval for leukemia drug
    Reuters

    AstraZeneca shares rise on early U.S. approval for leukemia drug

    AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie . AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults.

  • Reuters - UK Focus

    UPDATE 2-FTSE enjoys best day since July; mid-caps gain for 4th week

    London's FTSE 100 surged more than 1% on Friday after two days of selling, as investors turned cautiously optimistic about a Sino-U.S. trade deal and exporter stocks rose after the pound weakened on downbeat U.K. Purchasing Managers' Indexes (PMI) data. The FTSE 250 added 0.6%, though gains were capped by data that showed British business this month suffered its deepest downturn since mid-2016 amid uncertainty around the general election and Brexit. Further keeping gains in check was a 9% slide in Hochschild Mining after its 2020 output targets disappointed, and an 8% drop in thread manufacturer Coats Group after it warned on annual profit.

  • Reuters - UK Focus

    UPDATE 1-BT will maintain ties with skills group if it drops Prince Andrew as patron

    Britain's BT has told a company promoting digital skills it would continue working with it if it dropped Prince Andrew as a patron. The British royal has been engulfed in a growing scandal since he gave a TV interview on Saturday to discuss his friendship with Jeffrey Epstein, who killed himself in a U.S. prison in August while awaiting trial on sex trafficking charges. Andrew denied an allegation that he had sex with a 17-year-old girl procured for him by Epstein but said he did not regret the friendship.

  • Reuters - UK Focus

    UPDATE 1-Company logos vanish from Prince Andrew's website as sex scandal grows

    A scheme for entrepreneurs founded by Prince Andrew has taken down the logos of its corporate sponsors from its website, as firms and charities distance themselves from the British royal over a sex scandal. Andrew, Queen Elizabeth's second son, denies an allegation that he had sex with a 17-year-old girl procured for him by his friend Jeffrey Epstein, who killed himself in a U.S. prison in August while awaiting trial on sex trafficking charges. The scandal has escalated since Andrew's rambling denials and explanations in a disastrous TV interview aired on Saturday left many viewers incredulous, and his apparent lack of compassion for Epstein's victims drew widespread condemnation.

  • Why the Astrazeneca share price (LON:AZN) could go higher
    Stockopedia

    Why the Astrazeneca share price (LON:AZN) could go higher

    Stockopedia’s own data points to a jarringly simple stock market truth amidst the daily whirlwind of financial data: share prices that have gone up tend to kee8230;

  • Reuters - UK Focus

    UPDATE 2-European stocks end flat as defensive gains offset auto slide

    European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector. The pan-European STOXX 600 index finished little changed, after having spent most of the session in negative territory. The European automobiles and parts sector dropped 2.1%, its steepest fall in about four weeks, with Germany's Volkswagen leading declines after it slashed its operating profit and sales growth outlook due to slowdown in the auto sector.

  • Reuters - UK Focus

    UPDATE 2-Election polls thrust UK midcaps to 14-month high

    UK mid-caps closed at their highest level in nearly 14 months on Monday, boosted by polls pointing to victory by the ruling Conservatives in upcoming elections, while a near 5% drop in insurer Aviva weighed on the main board. The domestically-focused FTSE 250 index rose 0.2% while the FTSE 100 added 0.1%.

  • Reuters - UK Focus

    UPDATE 2-FTSE dips on murky trade view; Tullow tanks on mid-caps

    London's main bourse retreated on Wednesday as traders grew weary of mixed trade signals from U.S. President Donald Trump, while mid-caps slid on the back of weak economic data and a plunge in Tullow Oil. The more internationally-exposed FTSE 100 fell 0.2%, trimming some early losses as exporter stocks such as Diageo and AstraZeneca benefited from a weaker pound. The jump in exporter shares also helped the bourse outperform the broader European benchmark index.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more